Abstract

Tumor-associated macrophages (TAMs) affect cancer progression and therapy. Ovarian carcinoma often metastasizes to the peritoneal cavity. Here, we found 2 peritoneal macrophage subsets in mice bearing ID8 ovarian cancer based on T cell immunoglobulin and mucin domain containing 4 (Tim-4) expression. Tim-4+ TAMs were embryonically originated and locally sustained while Tim-4– TAMs were replenished from circulating monocytes. Tim-4+ TAMs, but not Tim-4– TAMs, promoted tumor growth in vivo. Relative to Tim-4– TAMs, Tim-4+ TAMs manifested high oxidative phosphorylation and adapted mitophagy to alleviate oxidative stress. High levels of arginase-1 in Tim-4+ TAMs contributed to potent mitophagy activities via weakened mTORC1 activation due to low arginine resultant from arginase-1–mediated metabolism. Furthermore, genetic deficiency of autophagy element FAK family-interacting protein of 200 kDa resulted in Tim-4+ TAM loss via ROS-mediated apoptosis and elevated T cell immunity and ID8 tumor inhibition in vivo. Moreover, human ovarian cancer–associated macrophages positive for complement receptor of the immunoglobulin superfamily (CRIg) were transcriptionally, metabolically, and functionally similar to murine Tim-4+ TAMs. Thus, targeting CRIg+ (Tim-4+) TAMs may potentially treat patients with ovarian cancer with peritoneal metastasis.

Highlights

  • Ovarian cancer frequently metastasizes to the peritoneal cavity as manifested by ascites fluid formation and a large number of tumor islets distributing to the peritoneum, omentum, and serosal surfaces of the viscera

  • Peritoneal residential macrophage subsets are poorly understood in ovarian cancer

  • Mouse macrophages are traditionally classified into 2 subsets: F4/80hiMHC-IIlo and F4/80loMHC-IIhi

Read more

Summary

Introduction

Ovarian cancer frequently metastasizes to the peritoneal cavity as manifested by ascites fluid formation and a large number of tumor islets distributing to the peritoneum, omentum, and serosal surfaces of the viscera. Tumor-associated macrophages (TAMs) constitute over 50% of cells in the peritoneal tumor implants and the ascites fluids in patients with peritoneal ovarian cancer metastasis. Previous studies in mouse models have shown that peritoneal TAMs generally promoted ovarian cancer metastasis and inhibited immunity [5,6,7]. These observations suggest that TAMs may be an ideal target for cancer immunotherapy [3]. Following this thought, different approaches — including targeting TAM trafficking, switching their functions, and developing TAM-depleting antibody — have been tested in preclinical models [8].

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.